Annandale, VA; May 31, 2022admin4821
The COVID-19 Battle Continues with the Development of a New Preventive
The leaders and researchers at the Clinical Alliance for Research and Education-Infectious Diseases (CARE-ID) are very pleased to announce their collaboration with Astra Zeneca for a new clinical trial (ENDURE) of its combination product of 2 monoclonal antibodies for pre-exposure prophylaxis (prevention) of COVID-19. The study will be a Phase II, randomized, open-label, multicenter, dose-ranging study.
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, has reported: “Recent data from its Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s Evusheld (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and by 83% in the six-month follow-up analysis, compared to placebo.”